ANI Pharmaceuticals, Inc.
ANIP
Key stats
- Open
- 71.56
- Day high
- 71.82
- Day low
- 70.00
- Previous close
- 71.09
- Volume
- 361.3K
- VWAP
- 71.11
- 52-week high
- 89.57
- 52-week low
- 67.14
- Market cap
- 1.62B
- Shares out
- 22.96M
- Employees
- 970
- Listed
- 1999
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
PHARMACEUTICAL PREPARATIONS · PRINCETON, NJ · anipharmaceuticals.com
Options · expiring Nov 20
Nov 12, 3:59 PM ET- Call open interest
- 50
- Put open interest
- 34
- Put/call
- 0.68
- At-the-money IV
- 45.3%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 80 call | 0.17 | Nov 6, 12:51 PM | 31 | 32 | 87.0% |
| 60 call | 9.50 | Nov 10, 12:49 PM | 3 | 3 | 70.1% |
| 70 call | 4.00 | Oct 19, 3:45 PM | 3 | 3 | 45.3% |
| 85 call | 0.10 | Nov 6, 9:30 AM | 2 | 2 | 92.5% |
| 65 call | 5.00 | Nov 6, 9:30 AM | 1 | 1 | 42.3% |
| 75 call | 0.98 | Nov 10, 1:31 PM | 1 | 9 | 97.1% |
Quarterly results
Massive · Nov 5, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $290.78M | $266.04M | $237.46M | $247.06M |
| Gross profit | $179.25M | $165.89M | $143.88M | $146.79M |
| Operating income | $52.37M | $40.46M | $38.89M | $34.85M |
| Net income | $32.72M | $23.00M | $27.43M | $25.39M |
| Diluted EPS | 1.51 | 1.05 | 1.28 | 1.08 |
| Operating cash flow | $83.79M | $56.67M | $58.38M | $30.37M |
| Assets | $1.57B | $1.49B | $1.42B | $1.44B |
| Liabilities | $930.55M | $896.90M | $859.67M | $899.65M |
| Equity | $637.11M | $597.21M | $562.30M | $540.72M |
Technicals
Massive · Nov 12, 2026- 50-day average72.32
- 200-day average77.06
- RSI (14 days)48.5
Short interest
Massive · Oct 30, 2026- Oct 30, 20263.58M shares · 11.9 days to cover
- Oct 15, 20263.47M shares · 10.1 days to cover
- Sep 30, 20263.49M shares · 7.2 days to cover
- Sep 15, 20262.49M shares · 7.4 days to cover
Splits
Massive · Jun 4, 2012- Jun 4, 20121-for-6
Related companies
MassiveNews coverage
No stories about ANI Pharmaceuticals, Inc. right now.